Tue Sep 10 14:37:00 UTC 2024: ## Icahn School of Medicine at Mount Sinai Partners with IPGaia for Drug Discovery

**New York, NY (September 10, 2024)** – The Icahn School of Medicine at Mount Sinai has entered into a research and development agreement with IPGaia Inc. (IPG), a subsidiary of the Healthcare New Platform Fund, to accelerate drug discovery. The agreement, signed on August 7th, 2024, will see Icahn Mount Sinai propose promising drug targets to IPG for development into clinical candidates.

IPG, known for its drug discovery platform, seeks to collaborate with leading research institutions worldwide to identify and develop new medicines. This partnership marks IPG’s 10th academic institution collaboration and its first in the United States.

“We look forward to working with IPGaia, enhancing efforts in drug discovery and addressing healthcare challenges,” said Erik Lium, PhD, Chief Commercial Innovation Officer at the Mount Sinai Health System and President of Mount Sinai Innovation Partners. “Their innovative platform will contribute to our shared goals in advancing early stage biomedical research.”

Yasu Yamaguchi, Ph.D., President and CEO of IPG, expressed enthusiasm for the partnership. “This partnership grants IPG access to cutting-edge drug discovery seeds, enabling us to develop highly innovative medicines with greater efficiency. In this sense, IPG is committed to addressing global challenges such as rising healthcare costs and extending healthy life expectancy.”

IPG’s platform aims to expedite the development of innovative pharmaceuticals at lower costs. This model promotes horizontal division of labor within the pharmaceutical industry, with IPG serving as a platform for generating pre-clinical stage medicines.

The Icahn School of Medicine at Mount Sinai is a leading medical research and education institution, ranked 13th nationwide in National Institutes of Health (NIH) funding. The school is dedicated to translational research and therapeutics, with a focus on areas like genomics, virology, and cardiology. Through its technology transfer office, Mount Sinai fosters the commercialization of its research discoveries for public benefit.

This collaboration between IPGaia and Icahn Mount Sinai is expected to lead to the development of new and effective treatments for a range of diseases, while contributing to a more efficient and affordable healthcare system.

Read More